Northern Trust’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11M Buy
581,600
+53,113
+10% +$859K ﹤0.01% 2013
2025
Q4
$9.24M Sell
528,487
-17,775
-3% -$334K ﹤0.01% 2124
2025
Q3
$11.3M Buy
546,262
+14,634
+3% +$355K ﹤0.01% 2043
2025
Q2
$11.3M Sell
531,628
-312,022
-37% -$7.12M ﹤0.01% 1995
2025
Q1
$16.3M Sell
843,650
-27,752
-3% -$557K ﹤0.01% 1754
2024
Q4
$15.6M Buy
871,402
+14,075
+2% +$273K ﹤0.01% 1853
2024
Q3
$18.8M Sell
857,327
-102,976
-11% -$1.44M ﹤0.01% 1657
2024
Q2
$7.49M Sell
960,303
-112,411
-10% -$607K ﹤0.01% 2161
2024
Q1
$4.44M Sell
1,072,714
-35,375
-3% -$141K ﹤0.01% 2544
2023
Q4
$2.89M Buy
1,108,089
+39,590
+4% +$81.4K ﹤0.01% 2797
2023
Q3
$2M Buy
1,068,499
+38,457
+4% +$73.3K ﹤0.01% 2941
2023
Q2
$2.59M Buy
1,030,042
+963,409
+1,446% +$1.76M ﹤0.01% 2861
2023
Q1
$117K Buy
66,633
+16,139
+32% +$44K ﹤0.01% 4046
2022
Q4
$215K Buy
50,494
+27,591
+120% +$50.2K ﹤0.01% 3833
2022
Q3
$27K Buy
+22,903
New +$25.9K ﹤0.01% 4487
2022
Q2
Sell
-175,682
Closed -$431K 4805
2022
Q1
$431K Sell
175,682
-17,120
-9% -$43.2K ﹤0.01% 3789
2021
Q4
$518K Sell
192,802
-1,264
-0.7% -$6.08K ﹤0.01% 3800
2021
Q3
$972K Buy
194,066
+159,811
+467% +$1.15M ﹤0.01% 3568
2021
Q2
$256K Buy
+34,255
New +$225K ﹤0.01% 4043

Other funds holding SMMT

Northern Trust's SMMT Position: Q1 2026 in Review

Northern Trust increased its Summit Therapeutics (SMMT) stake by 10% in Q1 2026, buying an estimated $859K and bringing the position to 581,600 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Northern Trust first reported a position in SMMT in Q2 2021 and has held it in 19 quarters since. The position peaked at $18.8M in Q3 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Northern Trust held 581,600 shares of Summit Therapeutics worth $11M as of Q1 2026.
  • Northern Trust bought 53,113 Summit Therapeutics shares in Q1 2026, an estimated $859K.
  • Summit Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2013 holding.
  • Northern Trust first reported a position in Summit Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Northern Trust's Summit Therapeutics position peaked at $18.8M in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.